Table 1.

Baseline and 6-Month Changes in Glycosylated Hemoglobin Values According to Treatment Group, Anti-Glutamic Acid Decarboxylase Antibody Concentration, and C-Peptide Concentration

	Pump treatment			MDI treatment
Analyte, concentration range	n	A1C (baseline) (%)	ΔA1C (%)	n	A1C (baseline) (%)	ΔA1C (%)	Comparing treatment groups
Anti-GAD Ab
<1 U/mL	135	9.0±0.76	−1.07±1.19	129	9.0±0.80	−0.44±1.13	P<0.0001
≥1 U/mL	27	8.9±0.67	−1.00±1.28	30	8.8±0.57	−0.24±0.86	P=0.01
Comparing anti-GAD groups			P=0.90			P=0.46
C-peptide
<156 pmol/L (<0.47 ng/mL)	43	9.0±0.61	−0.96±1.14	35	8.8±0.62	−0.10±0.97	P=0.002
≥156 to <309 pmol/L (≥0.47 to <0.93 ng/mL)	33	8.7±0.61	−0.94±1.11	48	8.9±0.67	−0.53±1.08	P=0.035
≥310 to <569 pmol/L (≥0.93 to <1.72 ng/mL)	40	9.0±0.92	−1.22±1.14	40	9.1±0.90	−0.63±1.06	P=0.012
≥569 pmol/L (≥1.72 ng/mL)	45	9.1±0.68	−1.07±1.41	35	9.1±0.81	−0.24±1.17	P=0.006
Comparing C-peptide quartiles			P=0.74			P=0.14

ΔA1C, change in glycosylated hemoglobin (A1C) from baseline to 6 months; Anti-GAD Ab, anti-glutamic acid decarboxylase antibody; MDI, multiple daily injection.